Oliver McCammon
Stock Analyst at LifeSci Capital
(4.82)
# 428
Out of 4,411 analysts
73
Total ratings
39.7%
Success rate
65.3%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Oliver McCammon
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CELC Celcuity | Maintained: Buy | $165 | $87.32 | +88.96% | 13 | Jun 2, 2026 | |
| CRBP Corbus Pharmaceuticals Holdings | Maintained: Buy | $38 | $7.88 | +382.23% | 9 | May 26, 2026 | |
| CATX Perspective Therapeutics | Maintained: Buy | $15 | $2.93 | +411.95% | 10 | May 16, 2026 | |
| CADL Candel Therapeutics | Rated: Buy | $16 | $7.97 | +100.75% | 5 | May 16, 2026 | |
| AURA Aura Biosciences | Maintained: Buy | $23 | $6.28 | +266.53% | 8 | May 16, 2026 | |
| INBX Inhibrx Biosciences | Maintained: Buy | $230 | $93.07 | +147.13% | 3 | May 16, 2026 | |
| JANX Janux Therapeutics | Rated: Buy | $60 | $13.70 | +337.96% | 12 | May 9, 2026 | |
| GLUE Monte Rosa Therapeutics | Maintained: Buy | n/a | $17.76 | - | 13 | May 7, 2026 |
Celcuity
Jun 2, 2026
Maintained: Buy
Price Target: $165
Current: $87.32
Upside: +88.96%
Corbus Pharmaceuticals Holdings
May 26, 2026
Maintained: Buy
Price Target: $38
Current: $7.88
Upside: +382.23%
Perspective Therapeutics
May 16, 2026
Maintained: Buy
Price Target: $15
Current: $2.93
Upside: +411.95%
Candel Therapeutics
May 16, 2026
Rated: Buy
Price Target: $16
Current: $7.97
Upside: +100.75%
Aura Biosciences
May 16, 2026
Maintained: Buy
Price Target: $23
Current: $6.28
Upside: +266.53%
Inhibrx Biosciences
May 16, 2026
Maintained: Buy
Price Target: $230
Current: $93.07
Upside: +147.13%
Janux Therapeutics
May 9, 2026
Rated: Buy
Price Target: $60
Current: $13.70
Upside: +337.96%
Monte Rosa Therapeutics
May 7, 2026
Maintained: Buy
Price Target: n/a
Current: $17.76
Upside: -